Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research Report), Quanterix ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

This disruption to Germany’s position as the leader in pharmaceuticals in the early ... And firms such as Vertex have added to the controversy with tough pricing demands for new therapies ...

The Department of Transportation sues Southwest Airlines for chronically delayed flights, joining recent actions against ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and Descovy. Read more here.

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...